Xencor Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Xencor kazanç ve gelirin sırasıyla yıllık 6.7% ve 29.2% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 14% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -42.5% olacağı tahmin edilmektedir.

Anahtar bilgiler

6.7%

Kazanç büyüme oranı

14.0%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.0%
Gelir büyüme oranı	29.2%
Gelecekteki özkaynak getirisi	-42.5%
Analist kapsamı	Good
Son güncelleme	08 Nov 2024

Gelecekteki son büyüme güncellemeleri

Xencor, Inc. (NASDAQ:XNCR) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 10

Recent updates

Xencor, Inc. (NASDAQ:XNCR) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 10

There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 29% Share Price Rise

Feb 27

Xencor: Standing Out With XmAb Technology

Feb 03

Xencor, Inc.'s (NASDAQ:XNCR) Business And Shares Still Trailing The Industry

Jan 05

Xencor, Inc. (NASDAQ:XNCR) Analysts Just Cut Their EPS Forecasts Substantially

Nov 13

Companies Like Xencor (NASDAQ:XNCR) Are In A Position To Invest In Growth

Nov 10

Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts

Aug 08

Xencor, Inc.'s (NASDAQ:XNCR) Shares May Have Run Too Fast Too Soon

Aug 12

Xencor GAAP EPS of -$0.57 misses by $0.10, revenue of $30.18M misses by $3.83M

Aug 03

Xencor: Capital-Efficient Platform Tech Play With A Lot Going On

Jun 03

Xencor, Inc. (NASDAQ:XNCR) Shares Could Be 35% Above Their Intrinsic Value Estimate

Feb 18

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGM:XNCR - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	171	-183	-172	-209	6
12/31/2025	115	-203	-226	-207	10
12/31/2024	59	-236	-202	-185	10
9/30/2024	85	-198	26	35	N/A
6/30/2024	134	-177	23	33	N/A
3/31/2024	162	-133	49	60	N/A
12/31/2023	168	-126	64	85	N/A
9/30/2023	145	-119	-151	-121	N/A
6/30/2023	113	-128	-136	-94	N/A
3/31/2023	98	-140	-64	-12	N/A
12/31/2022	165	-55	-19	24	N/A
9/30/2022	297	30	72	111	N/A
6/30/2022	289	22	45	73	N/A
3/31/2022	327	109	2	19	N/A
12/31/2021	275	83	-33	-17	N/A
9/30/2021	163	-4	-75	-62	N/A
6/30/2021	179	24	-42	-26	N/A
3/31/2021	124	-64	-58	-44	N/A
12/31/2020	123	-69	-19	-5	N/A
9/30/2020	84	-83	-55	-42	N/A
6/30/2020	71	-80	-55	-44	N/A
3/31/2020	77	-61	80	93	N/A
12/31/2019	157	27	53	64	N/A
9/30/2019	165	36	56	67	N/A
6/30/2019	172	49	54	63	N/A
3/31/2019	153	39	-82	-74	N/A
12/31/2018	41	-70	-89	-80	N/A
9/30/2018	59	-45	-77	-70	N/A
6/30/2018	30	-71	N/A	-63	N/A
3/31/2018	43	-53	N/A	-47	N/A
12/31/2017	46	-38	N/A	-34	N/A
9/30/2017	22	-55	N/A	-43	N/A
6/30/2017	30	-40	N/A	95	N/A
3/31/2017	84	15	N/A	98	N/A
12/31/2016	109	45	N/A	95	N/A
9/30/2016	103	40	N/A	107	N/A
6/30/2016	99	38	N/A	12	N/A
3/31/2016	34	-18	N/A	14	N/A
12/31/2015	28	-18	N/A	27	N/A
9/30/2015	12	-27	N/A	25	N/A
6/30/2015	9	-23	N/A	-20	N/A
3/31/2015	9	-19	N/A	-18	N/A
12/31/2014	10	-16	N/A	-21	N/A
9/30/2014	6	-19	N/A	-20	N/A
6/30/2014	8	-17	N/A	-19	N/A
3/31/2014	11	85	N/A	-12	N/A
12/31/2013	10	85	N/A	-5	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: XNCR önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: XNCR önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: XNCR önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: XNCR şirketinin gelirinin (yıllık 29.2% ) US pazarından (yıllık 9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: XNCR şirketinin gelirinin (yıllık 29.2% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: XNCR 3 yıl içinde kârsız olması bekleniyor.

Xencor Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Xencor, Inc. (NASDAQ:XNCR) Just Reported And Analysts Have Been Cutting Their Estimates

Consensus revenue estimates fall by 18%

Consensus EPS estimates upgraded to US$1.66 loss

Consensus revenue estimates increase by 52%

Price target decreased by 7.0% to US$40.50

Consensus revenue estimates increase by 19%

Recent updates

Xencor, Inc. (NASDAQ:XNCR) Just Reported And Analysts Have Been Cutting Their Estimates

Xencor, Inc. Doses First Subject in Phase 1/2 Study of XmAb®?942 in Development for Patients with Inflammatory Bowel Disease

Xencor Announces Dagmar Rosa-Bjorkeson Not Stand for Re-Election as Director

Xencor, Inc. has completed a Follow-on Equity Offering in the amount of $175.001111 million.

Xencor: Vudalimab Development Along With Hidden Gem Candidate

Xencor, Inc.'s (NASDAQ:XNCR) 34% Share Price Surge Not Quite Adding Up

Xencor, Inc. has filed a Follow-on Equity Offering.

Xencor, Inc. has completed a Follow-on Equity Offering in the amount of $175.001111 million.

Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR)

Does Xencor (NASDAQ:XNCR) Have A Healthy Balance Sheet?

Lacklustre Performance Is Driving Xencor, Inc.'s (NASDAQ:XNCR) Low P/S

Consensus revenue estimates fall by 18%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Xencor Appoints Bart Cornelissen as Senior Vice President

Is Xencor (NASDAQ:XNCR) Weighed On By Its Debt Load?

Co-Founder recently sold US$294k worth of stock

Co-Founder notifies of intention to sell stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 29% Share Price Rise

Xencor, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Insider notifies of intention to sell stock

Xencor: Standing Out With XmAb Technology

Xencor, Inc.'s (NASDAQ:XNCR) Business And Shares Still Trailing The Industry

Xencor, Inc. Appoints Dane Leone as Senior Vice President, Corporate Strategy

Co-Founder notifies of intention to sell stock

Consensus EPS estimates upgraded to US$1.66 loss

Consensus revenue estimates increase by 52%

Xencor, Inc. (NASDAQ:XNCR) Analysts Just Cut Their EPS Forecasts Substantially

Companies Like Xencor (NASDAQ:XNCR) Are In A Position To Invest In Growth

Price target decreased by 7.0% to US$40.50

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xencor, Inc. to Report Q3, 2023 Results on Nov 07, 2023

John J. Kuch to Retire as Chief Financial Officer of Xencor, Inc. in March 2024

Xencor, Inc. Appoints Barbara J. Klencke to Board of Directors

Consensus revenue estimates increase by 19%

Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xencor, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Co-Founder notifies of intention to sell stock

Xencor, Inc. Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress

Consensus EPS estimates fall by 20%

Insufficient new directors

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Co-Founder recently sold US$183k worth of stock

Consensus revenue estimates decrease by 13%

Full year 2022 earnings: EPS exceeds analyst expectations

Xencor, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Investor sentiment improves as stock rises 15%

Senior VP & Chief Medical Officer recently sold US$101k worth of stock

Senior VP & Chief Medical Officer notifies of intention to sell stock

Xencor, Inc. Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma At the American Society of Hematology Annual Meeting

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study

Xencor, Inc. to Report Q3, 2022 Results on Nov 07, 2022

High number of new directors

Xencor, Inc. to Present Seven Posters on Multiple Clinical Trials and Research-Stage Programs At the SITC Annual Meeting

High number of new directors

Xencbor, Inc. Announces the Appointment of Nancy Valente to Its Board of Directors

Xencor, Inc.'s (NASDAQ:XNCR) Shares May Have Run Too Fast Too Soon

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Xencor GAAP EPS of -$0.57 misses by $0.10, revenue of $30.18M misses by $3.83M

Xencor, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Investor sentiment improved over the past week

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 2000 Growth-Defensive Index

Investor sentiment improved over the past week

Xencor: Capital-Efficient Platform Tech Play With A Lot Going On

Xencor, Inc. Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors

Price target decreased to US$50.13